We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Efficacy & Safety Drug Study for Patients with Primary Immune Thrombocytopenia (ITP)

This study is currently closed to enrollment.

Phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, up to 31-week trial to evaluate the efficacy, safety, and impact on QoL of efgartigimod 10 mg/kg IV treatment in adult patients with primary ITP.

AGE: 18 years and older
GENDER: All
TYPE: Drug Study
HEALTHY PARTICIPANTS: No
CONDITION: Immune Thrombocytopenia

Study Purpose

University Hospitals Cleveland Medical Center is offering a research study to investigate the effect (efficacy) and the safety of a drug called “efgartigimod (ARGX-113)” in people with primary immune thrombocytopenia (ITP). The study will collect information on how well efgartigimod works, how your body processes efgartigimod, what efgartigimod does to your body, and how your immune system reacts to efgartigimod.